Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

BackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or reg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	colorectal cancer camrelizumab immune checkpoint inhibitor microsatellite stable bevacizumab regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1778ffc6421b4cb1aa24fb47cd56073e
record_format	dspace
spelling	oai:doaj.org-article:1778ffc6421b4cb1aa24fb47cd56073e2021-12-01T03:11:20ZPreliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study2234-943X10.3389/fonc.2021.774445https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.774445/fullhttps://doaj.org/toc/2234-943XBackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC.Materials and MethodsMedical records of mCRC patients who received camrelizumab and XELOX plus bevacizumab or regorafenib at the First Hospital of Quanzhou Affiliated to Fujian Medical University between June 1, 2019, and April 30, 2021, were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and side effects of the drug were recorded and reviewed.ResultsTwenty-five eligible patients received combination therapy, including bevacizumab in 19 patients and regorafenib in 6. Twenty-one patients had pMMR/MSS and one MSI-H. Of the 25 patients who could be evaluated for efficacy, 18 (72%) achieved PR, 6 (24%) achieved SD, and 1 (4%) achieved PD. The ORR and DCR were 72% (18/25) and 96% (24/25), respectively. The median progression-free survival (PFS) was 11.2 months (95% CI 8.9–13.9), and OS had not yet been reached. The combination regimen of regorafenib in six (24%) patients was unassociated with treatment outcomes. Most AEs were either grade 1 or 2, and treatment-related grade 3 toxicities were observed in 8/25 (32%) patients.ConclusionCamrelizumab combined with XELOX plus bevacizumab or regorafenib was feasible, producing high rates of responses as first-line therapy in unselected Chinese patients with MSS mCRC. The toxicities were generally tolerable and manageable. Prospective randomized trials with large sample sizes are needed to evaluate these findings.Hong ZhouYuehui WangYanfang LinWenjie CaiXiaofeng LiXiaomeng HeFrontiers Media S.A.articlecolorectal cancercamrelizumabimmune checkpoint inhibitormicrosatellite stablebevacizumabregorafenibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	colorectal cancer camrelizumab immune checkpoint inhibitor microsatellite stable bevacizumab regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	colorectal cancer camrelizumab immune checkpoint inhibitor microsatellite stable bevacizumab regorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hong Zhou Yuehui Wang Yanfang Lin Wenjie Cai Xiaofeng Li Xiaomeng He Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
description	BackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC.Materials and MethodsMedical records of mCRC patients who received camrelizumab and XELOX plus bevacizumab or regorafenib at the First Hospital of Quanzhou Affiliated to Fujian Medical University between June 1, 2019, and April 30, 2021, were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and side effects of the drug were recorded and reviewed.ResultsTwenty-five eligible patients received combination therapy, including bevacizumab in 19 patients and regorafenib in 6. Twenty-one patients had pMMR/MSS and one MSI-H. Of the 25 patients who could be evaluated for efficacy, 18 (72%) achieved PR, 6 (24%) achieved SD, and 1 (4%) achieved PD. The ORR and DCR were 72% (18/25) and 96% (24/25), respectively. The median progression-free survival (PFS) was 11.2 months (95% CI 8.9–13.9), and OS had not yet been reached. The combination regimen of regorafenib in six (24%) patients was unassociated with treatment outcomes. Most AEs were either grade 1 or 2, and treatment-related grade 3 toxicities were observed in 8/25 (32%) patients.ConclusionCamrelizumab combined with XELOX plus bevacizumab or regorafenib was feasible, producing high rates of responses as first-line therapy in unselected Chinese patients with MSS mCRC. The toxicities were generally tolerable and manageable. Prospective randomized trials with large sample sizes are needed to evaluate these findings.
format	article
author	Hong Zhou Yuehui Wang Yanfang Lin Wenjie Cai Xiaofeng Li Xiaomeng He
author_facet	Hong Zhou Yuehui Wang Yanfang Lin Wenjie Cai Xiaofeng Li Xiaomeng He
author_sort	Hong Zhou
title	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
title_short	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
title_full	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
title_fullStr	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
title_full_unstemmed	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
title_sort	preliminary efficacy and safety of camrelizumab in combination with xelox plus bevacizumab or regorafenib in patients with metastatic colorectal cancer: a retrospective study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e
work_keys_str_mv	AT hongzhou preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy AT yuehuiwang preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy AT yanfanglin preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy AT wenjiecai preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy AT xiaofengli preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy AT xiaomenghe preliminaryefficacyandsafetyofcamrelizumabincombinationwithxeloxplusbevacizumaborregorafenibinpatientswithmetastaticcolorectalcanceraretrospectivestudy
_version_	1718405887940362240

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

Ejemplares similares